Publications by authors named "T E Albertson"
Background: Drug overdose-related deaths continue to increase globally. Testing demands have likewise increased, prompting healthcare facilities to adopt a range of methods, from simple point-of-care immunoassays to comprehensive chromatographic and mass spectrometry-based techniques. Each of these testing methods has trade-offs related to cost, performance, speed, and convenience, requiring healthcare facilities to carefully determine the best options to meet their clinical needs.
View Article and Find Full Text PDFArticle Synopsis
- - The study examines how exposure to wildfire smoke impacts immune responses in individuals receiving the Pfizer COVID-19 vaccine, focusing on the role of Natural Killer (NK) cells.
- - Researchers analyzed blood samples from 52 participants before and after vaccine administration during heavy wildfire smoke events, finding variations in IgG antibody levels associated with air quality.
- - Results indicate that wildfire smoke exposure may disrupt immune function by affecting NK cell activity, leading to reduced vaccine efficacy over time.
Article Synopsis
- Rattlesnake envenomations are common in the U.S., with two main antivenoms available: CroFab® and ANAVIP®.
- A study reviewed 481 cases of rattlesnake bites treated with these antivenoms between 2018 and 2022, focusing on adverse effects.
- Results show that CroFab® had a higher rate of severe adverse events (1.5%) compared to ANAVIP®, which had none, indicating that both antivenoms are generally safe but ANAVIP® may have a better safety profile.
Update on the pharmacological treatment of chronic obstructive pulmonary disease.
Expert Opin Pharmacother
October 2024
Article Synopsis
- Chronic obstructive pulmonary disease (COPD) is often caused by smoking and environmental factors, with recent advancements in treatment becoming available.
- The text discusses the effectiveness of various treatments, including bronchodilators, corticosteroids, and new PDE inhibitors like ensifentrine, alongside the strategic use of antibiotics and biologics for specific cases.
- The introduction of these new therapies complicates COPD management, highlighting the importance of understanding patient characteristics (endotypes and phenotypes) to guide treatment choices, though they can be costly.
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF).
Expert Rev Clin Pharmacol
September 2024
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive-fibrosing lung disease with a median survival of less than 5 years. Currently, two agents, pirfenidone and nintedanib are approved for this disease, and both have been shown to reduce the rate of decline in lung function in patients with IPF. However, both have significant adverse effects and neither completely arrest the decline in lung function.
View Article and Find Full Text PDF